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Highlights of the International AIDS Society Conference 
Almost 6000 delegates attended 
the ﬁ   fth International AIDS Society 
Conference on Pathogenesis, Treatment 
and Prevention in Cape Town, South 
Africa (July 19–22). The conference 
highlighted advances in basic and 
clinical science and biomedical 
prevention, and included a new track 
on operational research.
Basic science
The role of host genetics in HIV 
disease progression is increasingly 
well understood. In a plenary session 
Amalio Telenti (Institute of Medical 
Microbiology, Geneva, Switzerland) 
showed that 22% of population 
variance in viral load can be explained 
by common genetic variants, demo-
graphics, and population factors. The 
use of such data might help clinicians 
predict disease progression. Telenti also 
summarised evidence on the relation 
between genetic determinants and 
plasma-drug concentrations for several 
drugs that could provide guidance for 
dose-adjustment, potentially reducing 
cost and toxicity.
Clinical science
Results from two drug trials held 
promise for treatment simpliﬁ  cation in 
developed countries. Both the MONOI 
(abstract WELB102) and MONET 
(TUAB106-LB) trials reported non-
inferior eﬃ   cacy at week 48 of darunavir 
or ritonavir monotherapy vs darunavir 
or ritonavir plus nucleoside reverse 
transcriptase inhibitors. Switching to 
monotherapy would be expected to 
provide simpler dosing and to reduce 
treatment costs. For developing 
countries, presentations focused on 
earlier treatment initiation. Data from a 
randomised trial in Haiti (CIPRAHT001) 
provided strong evidence that early 
treatment initiation improves survival. 
The study, which was stopped early, 
found a four-fold reduction in mortality 
and a two-fold reduction in incident 
tuberculosis among patients who 
started treatment earlier (CD4 350 
cells per μL) compared with those who 
started later (CD4 <200 cells per μL). 
Treating earlier will cost more in the 
short term, but long-term cost savings 
are expected as overall incidence of 
opportunistic infections will be reduced. 
A few days after the conference the 
South African government announced 
a revision to its treatment guidelines, 
including earlier initiation.
Biomedical prevention
Results of all completed trials of control 
of sexually transmitted diseases, 
microbicides, pre-exposure prophylaxis, 
HIV vaccines, and male circumcision 
were summarised in a plenary address 
Ronald Gray (Johns Hopkins, MD, 
USA). Of 28 trials done to date, only 
four have reported signiﬁ  cant eﬃ   cacy 
(three of male circumcision), leading 
to calls for fewer trials of better 
quality and a renewed emphasis on 
basic science, particularly for vaccine 
development. A plenary by Reuben 
Granich (WHO, Geneva) examined 
the potential role of antiretroviral 
treatment as a means of preventing 
transmission, following the publication 
of a model in the Lancet suggesting a 
reduction in prevalence to below 1% 
by 2050 (Lancet 2009; 373:  48–57). 
Two presentations supported the role 
of increased antiretroviral coverage 
to prevent other infections: a study 
from Uganda (TUPDB104) showed 
that malaria incidence fell by 75% over 
a 4-year period as HAART coverage 
increased, whereas a study from South 
Africa (WELBB105) found three-fold 
reduction in tuberculosis prevalence 
over a 3-year period among HIV-
positive individuals. Data from ﬁ  ve 
studies supported the safety and 
eﬃ   cacy of providing HAART to mothers 
during pregnancy and after delivery to 
reduce vertical transmission. Among 
these, a randomised comparison of 
two triple-therapy combinations 
done in Botswana (WELBB101) 
found that vertical transmission 
reduced to 1% among breastfeeding 
mothers receiving HAART. A ﬁ  ve-
country trial (LBPEC01) that randomly 
assigned pregnant women to triple 
therapy or short-course prophylaxis 
(as recommended by WHO) found a 
42% decrease in HIV transmission in 
the HAART group. These studies call 
for an urgent review of current WHO 
guidelines.
Operational research
In rural sub-Saharan Africa, access 
to treatment is commonly denied 
to patients who live far from health 
centres. A cluster-randomised trial of 
facility versus home-based care done 
jointly by researchers at the London 
School of Hygiene and Tropical Medicine 
and the Ugandan non-governmental 
organisation TASO (MOAD101) found 
no diﬀ  erence in terms of mortality and 
virological suppression. Median annual 
costs for patients accessing care were 
ﬁ   ve-times less via the home-based 
approach. Another important barrier to 
accessing care is the chronic shortage 
of doctors to provide antiretroviral 
therapy. To overcome this, nurse-based 
models of care have been proposed. Two 
studies—a randomised trial from South 
Africa (LBPED03) and a concordance 
study from the Democratic Republic 
of the Congo (TUPED133)—found 
no diﬀ   erence in the performance of 
doctors and nurses in the provision of 
ART care, providing reassuring evidence 
of eﬀ  ectiveness.
AIDS in the recession
Studies pointed to the need to improve 
the current AIDS response by treating 
earlier, with better drugs. At the same 
time, the global HIV response faces a 
40% funding gap: 6·7 million are still 
without treatment and 2·7 million 
people are newly infected each year. 
The challenge in moving forward lies 
in ﬁ  nding the balance between what 
science says should be done and what 
economic reality allows.
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